Pacific Biosciences Of California (PACB) Revenue (2010 - 2026)

Pacific Biosciences Of California has reported Revenue for 17 years, with the latest figure at $37.2 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue changed 0.07% year-over-year to $37.2 million; the trailing twelve-month figure through Mar 2026 stood at $160.0 million (up 5.04% YoY), and the FY2025 full-year result was $160.0 million, up 3.89% from the prior year.
• Revenue for Q1 2026 stood at $37.2 million, down from $44.6 million in the prior quarter.
• The five-year high for Revenue was $58.4 million in Q4 2023, with the low at $27.4 million in Q4 2022.
• Average Revenue over 5 years is $40.0 million, with a median of $38.8 million recorded in 2024.
• Year-over-year, Revenue surged 113.35% in 2023 and tumbled 32.79% in 2024.
• Tracing PACB's Revenue over 5 years: stood at $27.4 million in 2022, then soared by 113.35% to $58.4 million in 2023, then plunged by 32.79% to $39.2 million in 2024, then gained by 13.82% to $44.6 million in 2025, then declined by 16.73% to $37.2 million in 2026.
• The last three Revenue figures came in at $37.2 million (Q1 2026), $44.6 million (Q4 2025), and $38.4 million (Q3 2025), per Business Quant data.

Peer Comparison